Prolonged Administration of Temozolomide in Adult Patients with Anaplastic Glioma

被引：0

作者：

Freyschlag, C. F. ^{[1
]}

Smolczyk, D. R. ^{[2
]}

Janzen, E. ^{[2
]}

Schmieder, K. ^{[2
]}

Thome, C. ^{[1
]}

Lohr, F. ^{[3
]}

Wenz, F. ^{[3
]}

Weiss, C. ^{[4
]}

Tuettenberg, J. ^{[5
]}

Seiz, M. ^{[1
]}

机构：

[1] Innsbruck Med Univ, Dept Neurosurg, A-6020 Innsbruck, Austria

[2] Univ Med Ctr Mannheim, Dept Neurosurg, Mannheim, Germany

[3] Univ Med Ctr Mannheim, Dept Radiat Oncol, Mannheim, Germany

[4] Univ Med Ctr Mannheim, Dept Biomed Stat, Mannheim, Germany

[5] SHG Klinikum Idar Oberstein, Dept Neurosurg, Idar Oberstein, Germany

来源：

ANTICANCER RESEARCH | 2011年 / 31卷 / 11期

关键词：

Anaplastic gliomas; long-term administration; temozolomide; PHASE-III TRIAL; MALIGNANT GLIOMA; SURVIVAL;

D O I：

暂无

中图分类号：

R73 [肿瘤学];

学科分类号：

100214 ;

摘要：

Purpose: Prolonged administration of temozolomide is widely used in patients with glioblastoma; whereas the treatment of anaplastic glioma differs between neurooncological centres. The safety, feasibility and efficacy of prolonged temozolomide administration in patients with anaplastic gliomas was evaluated. Patients and Methods: Forty-two patients with primary, recurrent or secondary anaplastic glioma were retrospectively analysed for the course of their disease. Treatment mostly consisted of surgery, followed by radiotherapy with concomitant and adjuvant temozolomide. In Jive patients with recurrence of primary anaplastic glioma, chemotherapy was initiated without previous surgery. Temozolomide was administered until evidence of tumour recurrence, appearance of serious side-effects or patients' wish to finish chemotherapy. Results: The median overall survival (OS) was 39 months with a median cycle number of 7.5 (1-42). Treatment with temozolomide was stopped in 12 patients due to side-effects in general, whereas in only three patients (7.1%) treatment had to be discontinued due to haematological side-effects. There was no evidence of treatment related infections or grade IV toxicity. Extent of surgery had a significant influence on OS in anaplastic gliomas, the number of adjuvant temozolomide cycles showed a positive influence as well on time to progression (TTP) and OS. Conclusion: Prolonged administration of adjuvant temozolomide is safe and can be favorable for patients with ana plastic gliomas.

引用

页码：3873 / 3877

页数：5